Segment reporting (Tables)

12 Months Ended

Dec. 31, 2024

Segment reporting [Abstract]

Revenues and Adjusted EBITDA and Group Adjusted EBITA, by Segments

3.1. Segment performance

	Precision Medicine			Therapeutics			Manufacturing Solutions			Total segment
2024		A$’000			A$’000			A$’000			A$’000
Revenue from contracts with customers		771,106			9,351			2,750			783,207
Cost of sales		(270,821	)		-			(2,708	)		(273,529	)
Gross profit		500,285			9,351			42			509,678
Research and development costs		(111,348	)		(82,582	)		(707	)		(194,637	)
Selling and marketing expenses		(84,562	)		(136	)		(775	)		(85,473	)
Manufacturing and distribution costs		(7,807	)		(4	)		(17,920	)		(25,731	)
General and administration costs		(42,800	)		(92	)		(5,801	)		(48,693	)
Other losses (net)		(8,909	)		-			123			(8,786	)
Operating profit/(loss)		244,859			(73,463	)		(25,038	)		146,358
Other losses (net)		8,909			-			(123	)		8,786
Depreciation and amortization		5,573			-			1,293			6,866
Adjusted earnings before interest, tax, depreciation and amortization		259,341			(73,463	)		(23,868	)		162,010

	Precision Medicine			Therapeutics			Manufacturing Solutions			Total segment
2023	A$’000			A$’000			A$’000			A$’000
Revenue from contracts with customers		496,738			5,391			418			502,547
Cost of sales		(188,157	)		-			-			(188,157	)
Gross profit		308,581			5,391			418			314,390
Research and development costs		(80,327	)		(47,566	)		(644	)		(128,537	)
Selling and marketing expenses		(49,991	)		(118	)		-			(50,109	)
Manufacturing and distribution costs		(7,601	)		(76	)		(2,192	)		(9,869	)
General and administration costs		(30,979	)		(127	)		(3,516	)		(34,622	)
Other losses (net)		(35,138	)		-			-			(35,138	)
Operating profit/(loss)		104,545			(42,496	)		(5,934	)		56,115
Other losses (net)		35,138			-			-			35,138
Depreciation and amortization		5,511			45			231			5,787
Adjusted earnings before interest, tax, depreciation and amortization		145,194			(42,451	)		(5,703	)		97,040

	Precision Medicine			Therapeutics			Manufacturing Solutions			Total segment
2022		A$’000			A$’000			A$’000			A$’000
Revenue from contracts with customers		156,369			3,727			-			160,096
Cost of sales		(65,170	)		-			-			(65,170	)
Gross profit		91,199			3,727			-			94,926
Research and development costs		(48,285	)		(32,402	)		-			(80,687	)
Selling and marketing expenses		(36,313	)		-			-			(36,313	)
Manufacturing and distribution costs		(2,564	)		(12	)		(1,373	)		(3,949	)
General and administration costs		(23,807	)		-			(775	)		(24,582	)
Other losses (net)		(17,496	)		10			-			(17,486	)
Operating profit/(loss)		(37,266	)		(28,677	)		(2,148	)		(68,091	)
Other losses (net)		17,496			(10	)		-			17,486
Depreciation and amortization		4,679			40			21			4,740
Adjusted earnings before interest, tax, depreciation and amortization		(15,091	)		(28,647	)		(2,127	)		(45,865	)

3.2. Reconciliation of total segment adjusted EBITDA to profit/(loss) before income tax

		2024			2023			2022
	Note		A$’000			A$’000			A$’000
Total segment adjusted EBITDA			162,010			97,040			(45,865	)
Unallocated income, expenses and eliminations:
General and administration costs			(81,137	)		(39,559	)		(22,574	)
Other gains/(losses) (net)	9		8,123			(35,854	)		(18,751	)
Finance income			10,862			1,019			1
Finance costs	10		(36,936	)		(13,772	)		(6,693	)
Depreciation and amortization			(6,866	)		(5,787	)		(4,740	)
Profit before income tax			56,056			3,087			(98,622	)

Operating Segment Assets and Liabilities

3.3. Operating segment assets and liabilities

	Precision Medicine		Therapeutics		Manufacturing Solutions		Total segment		Reconciling items		Group
December 31, 2024	A$’000		A$’000		A$’000		A$’000		A$’000		A$’000
Total assets		479,764		216,123		222,208		918,095		598,336		1,516,431
Total liabilities		240,618		16,869		86,377		343,864		604,354		948,218
Additions to non- current assets		2,427		139,876		168,534		310,837		513		311,350

	Precision Medicine		Therapeutics		Manufacturing Solutions		Total segment		Reconciling items		Group
December 31, 2023	A$’000		A$’000		A$’000		A$’000		A$’000		A$’000
Total assets		216,180		41,917		36,835		294,932		111,026		405,958
Total liabilities		180,379		18,709		20,172		219,260		37,787		257,047
Additions to non-current assets		66,321		5,116		-		71,437		-		71,437

Geographical Information

3.4. Geographical information

	2024		2023		2022		2024		2023
	Revenue by location of customer		Revenue by location of customer		Revenue by location of customer		Non-current assets by location of asset		Non-current assets by location of asset
	A$’000		A$’000		A$’000		A$’000		A$’000
Australia		1,220		1,166		149		90,993		21,057
Belgium		546		458		564		100,637		77,469
Canada		2,542		1,272		456		126,419		-
United Kingdom		579		1,306		2,045		54,638		50,346
United States		762,308		489,657		150,006		173,591		4,130
Other countries		16,012		8,688		6,876		4,852		-
Total		783,207		502,547		160,096		551,130		153,002